Deerfield, Ill., February 6, 2012 and Osaka, Japan, February 7, 2012 - Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda ...
Blood pressure reductions statistically superior to olmesartan medoxomil-hydrochlorothiazide June 19, 2012 Results of a 12-week, head-to-head, phase 3 study published online in the American Heart ...
The US Food and Drug Administration (FDA) has approved Takeda Pharmaceutical's Edarbyclor (azilsartan medoxomil and chlorthalidone) for the treatment of hypertension to lower blood pressure in adults.
EDARBYCLOR (azilsartan medoxomil and chlorthalidone) 40/12.5mg, 40/25mg tablets by Takeda Takeda announced that the FDA has approved Edarbyclor (azilsartan medoxomil and chlorthalidone) for the ...
Takeda and Arbor enter into a license, development and commercialization agreement for EDARBI (azilsartan medoxomil) and EDARBYCLOR (azilsartan medoxomil and chlorthalidone) in the U.S. Under the ...
Takeda and Arbor enter into a license, development and commercialization agreement for EDARBI (azilsartan medoxomil) and EDARBYCLOR (azilsartan medoxomil and chlorthalidone) in the U.S. Under the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results